Acute exacerbations of COPD remain a common cause of morbidity and are associated with a sustained increase in the normal respiratory symptoms of dyspnoea, cough, and sputum volume and purulence. It has previously been shown that a change in cough symptoms occurs in 51.7% of exacerbations in COPD. We wish to record cough during a COPD exacerbation to determine whether this can be a objective marker of exacerbation duration and severity.

Acute exacerbations of COPD remain a common cause of morbidity and are associated with a sustained increase in the respiratory symptoms of dyspnoea, cough, sputum volume and sputum purulence. Cough is one of the most commonly reported and key symptoms in COPD patients. Cough can also be a useful factor in finding patients at risk of progressive airflow obstruction and cough along with the breathlessness is the major cause of distress in patients with chronic obstructive airways disease (COPD). There is limited literature looking into cough and COPD especially objective assessments.

in clinical practice and in most clinical trials scoring systems ie quality of life questionnaires or visual analogue scores, have been used to measure COPD exacerbation severity, although these may give an indication of the perceived severity of the symptom, they are inherently subjective and may be influenced by other factors. Shortfalls have prompted the development of cough recorders as an objective measure of this symptom. With this in mind we propose recruit 30 subjects with non-infective exacerbations of COPD and monitor their cough frequency as an inpatient in acute exacerbation and for 45 days post hospital discharge in order to elucidate the natural history of cough during and after an exacerbation.

Inclusion Criteria:

• Male/females aged between 40-80 years.
• Previous diagnosis of COPD.
• Acute exacerbation of COPD requiring treatment with antibiotics and/or corticosteroids.
• Symptoms of increased breathlessness, cough, sputum volume or sputum purulence.
• Acute exacerbation of COPD hospitalised within 48 hrs of study participation.
• On a stable therapeutic regimen for COPD for 8 weeks prior to inclusion.
• Known history of cigarette smoking at least 10 pack yrs.
• Willing and able to comply with study procedures.
• Able to provide written informed consent to participate.

Exclusion Criteria:

• Acute exacerbation of COPD within 8 weeks prior to inclusion.
• Clinically significant or unstable concurrent disease e.g. left ventricular failure, diabetes mellitus.
• On long-term oxygen therapy.

Hospital admissions